GSK: Core EPS up 5% in Q3
(CercleFinance.com) - GSK reports Q3 sales of £8,012m, up 2% at constant exchange rates and y-o-y.
Operating profit was £189m, down 86%, with an operating margin of 2.4%, down 20.6 pts. Core operating profit was £2,761m, up 5%.
EPS was -1.4 pence, with core EPS of 49.7 pence up 5%.
We recorded another quarter of growth in sales and core operating profit, as well as further good progress in R&D. Strong growth in specialty medicines helped to offset lower vaccine sales, and reflected successful new product launches in oncology and HIV, it says.
We also resolved the vast majority of our Zantac litigation during the quarter, removing uncertainty and allowing us to focus on the future. All this means that we are on track to achieve our 2024 guidance, and we are even more confident about our outlook for 2026 and 2031, it adds.
For 2024, GSK is targeting sales growth in 2024 of 7% to 9%, core operating profit growth of 11% to 13% and core EPS growth of 10% to 12%.
GSK announces a dividend of 15 pence for Q3 and confirms its dividend target of 60 pence for 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Operating profit was £189m, down 86%, with an operating margin of 2.4%, down 20.6 pts. Core operating profit was £2,761m, up 5%.
EPS was -1.4 pence, with core EPS of 49.7 pence up 5%.
We recorded another quarter of growth in sales and core operating profit, as well as further good progress in R&D. Strong growth in specialty medicines helped to offset lower vaccine sales, and reflected successful new product launches in oncology and HIV, it says.
We also resolved the vast majority of our Zantac litigation during the quarter, removing uncertainty and allowing us to focus on the future. All this means that we are on track to achieve our 2024 guidance, and we are even more confident about our outlook for 2026 and 2031, it adds.
For 2024, GSK is targeting sales growth in 2024 of 7% to 9%, core operating profit growth of 11% to 13% and core EPS growth of 10% to 12%.
GSK announces a dividend of 15 pence for Q3 and confirms its dividend target of 60 pence for 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.